Document:

Clinical Research Agreement

 Exhibit 10.39 
 CLINICAL RESEARCH AGREEMENT 
 THIS Clinical Research Agreement is entered into on the 3rd day of January, 2007 by and
between St. George’s Hospital Medical School (trading as St George’s, University of London), an exempt charity organized and existing under the laws of the United Kingdom, with its principal offices located at Cranmer Terrace, London SW17
ORE (hereinafter referred to as “SGUL”) and Mannatech, Inc., a corporation organized and existing under the laws of the State of Texas, USA, with its principal office located at 600 S. Royal Lane, Suite 200, Coppell,
Texas 75019 (hereinafter referred to as “MANNATECH”), jointly referred to as the Parties. 
 WHEREAS, MANNATECH and
SGUL have on-going research under a three (3) year Research Agreement for research in progress related to dietary supplementation with glyconutrients; 
 WHEREAS, MANNATECH and SGUL wish to expand the scope of the research as set forth herein; 
 WHEREAS, MANNATECH and SGUL have a mutual
interest in conducting research related to the dietary supplementation with glyconutrients, hereinafter referred to as the “RESEARCH”; 
 WHEREAS, MANNATECH desires to procure additional research services from SGUL, and SGUL further agrees to provide such additional services to MANNATECH; and 
 WHEREAS, MANNATECH and SGUL have a mutual interest in developing one or more products and services related to the dietary supplementation with glyconutrients
based on the results of the “PROJECT,” which may be the subject of a separate joint venture. 
 NOW, THEREFORE in
consideration of the premises and the mutual covenants hereinafter contained the sufficiency of which is expressly acknowledged, each party intending to be legally bound hereby, the parties agree as follows: 
  

	1.	Scope of Work 

 1.1 The Study to be performed under this Agreement shall be a study entitled “Ambrotose® Dosing and Optimization Studies,” (the
“Protocol”) which has heretofore been provided to MANNATECH and is incorporated into this Agreement in Appendix 1 by reference. SGUL certifies that, to its best knowledge, its facilities and population are adequate to
perform the Study contemplated by this Agreement and the Protocol. The Clinical Research and each Party’s activities described herein and in the Protocol shall be performed in accordance with the provisions of the Declaration of Helsinki, as
most recently revised, the relevant Good Clinical Practice (GCP) guidelines, as defined in the most recent ICH Harmonised Tripartite Guidelines and the EU directives 2001/20/EC and 2005/28/EC, as well as all relevant English laws and regulations.

 1.2 The minimum number of individuals enrolled in the Study for study under the protocol shall be six (6). 
  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 1 OF 10

 1.3 SGUL and Principal Investigator (named in Article 2 below) agree that all aspects of the Study will be conducted in
conformity with all applicable federal, state and local laws and regulations. SGUL further agrees not to conduct any research activities with Ambrotose which are contrary to the provisions of the Protocol or outside the scope of the Protocol.

  

	2.	Principal Investigator 

 2.1 The PROJECT will be supervised by
Prof. John S Axford, Director of the Sir Joseph Hotung Centre at SGUL, who with any sub-investigators shall be collectively referred to as “Principal Investigator”. Principal Investigator will be responsible for the direction and
supervision of all Study efforts in accordance with applicable SGUL policies, the Protocol and this Agreement. 
 2.2 In the event that the Principal
Investigator who signs either the Protocol and/or this Agreement leaves or is removed from the SGUL, then SGUL shall, within ten (10) days of such departure by Principal Investigator, provide written notice of such event to MANNATECH. Any
successor to Principal Investigator must be approved, in writing, by MANNATECH and such successor shall be required to agree to all the terms and conditions of the Protocol and this Agreement and to sign each such document as evidence of such
agreement (although failure to so sign will not relieve such successor from abiding with all the terms and conditions of the Protocol and this Agreement). 
 2.3 SGUL represents and warrants that it will not use in any capacity, in connection with any services to be performed under this Agreement, any individual who has been debarred pursuant to the Federal Food, Drug and Cosmetic Act or
equivalent English law. 
  

	3.	Project Monitor 

 3.1 It is agreed that Prof. John S Axford and
those designated by MANNATECH may, at mutually agreeable times during the Study and for a reasonable time after completion or early termination of the Study, arrange with the Principal Investigator or his/her designee: 
 3.1.1 to examine and inspect at regular business hours, SGUL facilities required for performance of the clinical trial; and 
 3.1.2 subject to applicable patient confidentiality considerations, to inspect, audit and to copy or have copied, all data and work product relating to
the Study conducted under this Agreement and to inspect and make copies of all data necessary for MANNATECH to confirm that the Study is being conducted in conformance with the Protocol and in compliance with all applicable legal and regulatory
requirements, including without limitation, any applicable requirements of the United States Food and Drug Administration or equivalent English law. 
  

	4.	Clinical Trial Approvals and Supplies 

 4.1. SGUL shall be
responsible for obtaining the following: 
 4.1.1 application for Ethics Committee approval of the Protocol, any informed consent relating to
the Study and advertisement, if any, pertaining to the 

  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 2 OF 10

 
enrollment of subjects in the Study by the appropriate Institutional Review Board (IRB) prior to beginning any study on human subjects. 
 4.1.2 an informed consent which complies with all applicable federal, state, and local laws and regulations signed by or on behalf of each human subject
prior to the subjects participating in the Study. 
 4.2 In the event SGUL’s IRB requires changes in the Protocol or informed consent, MANNATECH shall
be advised in advance and all modifications to the Protocol and informed consent must be approved in advance by MANNATECH. SGUL and the Principal Investigator shall not modify the Study described in the Protocol once finalized and after approval by
the IRB without the prior written approval of MANNATECH. 
 4.3 MANNATECH shall make available sufficient quantities of Ambrotose to carry out the Study, it
being understood that SGUL and the Principal Investigator shall take responsibility for and reasonable steps to maintain appropriate records and assure appropriate supply, handling, storage, distribution and usage of these materials in accordance
with the Protocol and any applicable laws and regulations relating thereto. Clinical supplies may not be used for any other purpose than that stated in the Protocol. All unused materials will be returned to MANNATECH by SGUL at the conclusion of the
Study, or upon earlier termination of this Agreement, unless written authorization to destroy or retain them is given by MANNATECH. If authorization to destroy unused material is given, SGUL shall provide MANNATECH with documentation of the method
of destruction. 
 4.4 MANNATECH shall serve as Clinical Trial Sponsor, in accordance with said GCP and Tripartite guidelines. 
  

	5.	Term 

 This Agreement shall be effective on upon approval by
MANNATECH’s Board of Directors and execution by both parties and shall continue for a one year period, unless terminated sooner or extended as hereinafter provided. 
  

	6.	Compensation 

 6.1 In consideration of research services to
be performed pursuant to this Agreement, MANNATECH shall make payments in the total amount of £254,436 (the “FEE”) in accordance with the costings detailed in Appendix 2. SGUL shall invoice MANNATECH for
expenses and work performed in connection with the PROJECT through 31 December 2006 (the equivalent of $200,000 USD or £102,237.81, as the case may be). SGUL shall invoice MANNATECH £102,237.81 during 2007 in quarterly installments,
based upon work performed and reports delivered to MANNATECH’s Board of Directors. MANNATECH shall withhold the balance remaining until Prof. Axford delivers his final report to and it is accepted by MANNATECH’s Board of Directors in 2008.
All payments shall be in Pounds Sterling. 
 6.2 Payment is due thirty (30) days after MANNATECH’s receipt of a complete invoice. 
  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 3 OF 10

 6.3 The Parties agree that the Fee shall not exceed £254,436. In the event the PROJECT fails to be completed
at the end of the Term, SGUL will conclude the PROJECT without further remuneration from MANNATECH. 
 6.4 The Parties agree that Mannatech shall own
all equipment purchased under the PROJECT as provided in Appendix 1 and the equipment shall be marked and inventoried accordingly. Upon completion of the PROJECT, Mannatech, at Mannatech’s sole expense and discretion, may collect the equipment.
SGUL shall provide reasonable access to Mannatech’s agents for moving the equipment, including after regular business hours if required by mutual agreement. 
  

	7.	Termination 

 7.1 MANNATECH has the option to review the
progress of the PROJECT upon each Anniversary Date of this Agreement and may elect to terminate the Agreement upon thirty (30) days written notice to SGUL prior to the respective Anniversary Date. In the event of early termination, MANNATECH
shall be under no further obligation to fund the PROJECT. 
 7.2 MANNATECH may terminate this Agreement at any time and without further financial obligation
if it is determined that the Lead Investigator’s hypothesis is flawed or if the data provided to MANNATECH in connection with the PROJECT is inadequate to support any scientific rationale for continuing the PROJECT. 
 7.3 The foregoing notwithstanding, this Agreement shall terminate prior to the expiration of the Term should any one or more of the following events occur: 

7.3.1 MANNATECH provides SGUL with sixty (60) days advance written notice; or 
 7.3.2 either party materially breaches the terms of this Agreement and the non-breaching party provides the other with thirty (30) days advance
written notice of termination and such breach is not remedied within such thirty (30) day period. 
 7.4 Except in the event of 7.3.2 above, in the
event of termination, MANNATECH shall reimburse SGUL for contractual commitments and financial obligations incurred by SGUL in performance of this Agreement prior to such termination, if such financial obligations or contractual commitments cannot
be canceled by SGUL. 
  

	8.	Ownership And Intellectual Property Rights  

 8.1 All
Background Information used or supplied under this Agreement shall remain the property of the party introducing the same. As regards SGUL, “Background Information” is defined herein as all information published by Prof. Axford or employees
of SGUL in a peer reviewed journal or information that SGUL can document in written or electronic form was affixed to a tangible medium of expression without funding from MANNATECH. As regards MANNATECH, “Background Information” is defined
herein as information that MANNATECH drafted, developed, created, purchased or licensed that MANNATECH can document in written or electronic form was affixed to a tangible medium of expression prior to the execution of this Agreement. 
 8.2 Principal Investigator shall submit an invention disclosure to SGUL and MANNATECH in written or electronic form for all developments, discoveries, trade 

  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 4 OF 10

 
secrets and inventions resulting from the performance of the PROJECT as soon as practicable. MANNATECH shall own all developments, discoveries, trade secrets
and inventions resulting from the performance of the PROJECT pursuant to the terms and conditions of this Agreement and in particular provisions 8.4 and 8.5. MANNATECH shall have the right to apply for, or to decide not to apply for, intellectual
property protection for such developments, discoveries and inventions at MANNATECH’s sole expense, provided, however, that MANNATECH agrees to promptly notify SGUL’s Head of Research Development and Enterprise and Lead Investigator at
least thirty (30) days before the filing of any application for intellectual property protection or within seven (7) days from MANNATECH decides not to apply for intellectual property protection, for such developments, discoveries and
inventions, but in any event prior to any public disclosure. Principal Investigator and those under his supervision shall execute any and all documents required to perfect MANNATECH’s rights thereto. 
 8.3 The Parties agrees to maintain any invention disclosures submitted by Lead Investigator to SGUL and MANNATECH pursuant to the terms and conditions of this Agreement
in confidence, and SGUL and Lead Investigator shall use reasonable efforts to prevent the disclosure of those inventions to third parties until the information in the disclosures becomes publicly available through no fault of the Parties.

 8.4 In the situation that a commercial joint venture is set up between MANNATECH and SGUL, it is agreed that any additional Intellectual Property that the
joint venture requires shall be governed by a separate license agreement to be negotiated by the parties at the time. 
 8.5 In the event that both Parties
agree that the invention has a commercial application, the Parties agree to enter into a Joint Venture Agreement by which SGUL and MANNATECH Gibraltar will jointly share in the profits of such commercial enterprise. It is hereby agreed that neither
party shall independently exploit any invention generated under this Agreement without entering into a joint venture unless agreed in writing by both Parties. 
 8.6 If MANNATECH applies for and is awarded a patent, it agrees to allow SGUL a royalty free license to use the technology on a non-commercial basis for research and teaching purposes, subject to the requirements to maintain the proprietary
nature of the invention. 
  

	9.	Confidential Information 

 9.1 Unless otherwise required by
law, SGUL will exercise reasonable effort to maintain in confidence proprietary or trade secret information disclosed or submitted to SGUL by MANNATECH which is designated in writing as confidential information at the time of disclosure
(“Confidential Information”) and will exercise reasonable efforts to maintain in confidence all proprietary or trade secret information by having those parties who are involved in the project sign a Confidentiality Agreement in the form
attached as Exhibit “A”. 
 9.2 Confidential Information does not include information which: 
 9.2.1 was known to SGUL prior to the disclosure hereunder; 
  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 5 OF 10

 9.2.2 was received from a third-party not under an obligation of confidence to SGUL; 
 9.2.3 is in the public domain at the time of disclosure or subsequently entered into the public domain without the fault of the recipient; 
 9.2.4 is independently known prior to receipt or is discovered independently by an employee or student of SGUL who had no access to the information
supplied by MANNATECH under this Agreement; or 
 9.2.5 is required to be disclosed by law. 
 9.3 The Parties agree to keep confidential all Intellectual Property and data disclosed by either party in the course of the PROJECT or this Agreement. 
 9.4 MANNATECH and SGUL may discuss the existence and the scope of the PROJECT. 
 9.5 SGUL retains the right to refuse to accept any such Confidential Information that is not considered to be essential to the completion of the PROJECT. The obligations of confidentiality of this paragraph shall survive and continue for a
period of ten (10) years after the termination of this Agreement. 
  

	10.	Publications 

 10.1 SGUL agrees to provide MANNATECH, in
confidence, with an advanced copy of any publication resulting from the PROJECT not less than sixty (60) days prior to the submission to a journal or any other public disclosure. MANNATECH shall have thirty (30) days in which it may
request changes to the manuscript and SGUL agrees to delay the publication for a period of at least sixty (60) days from the date the publication was originally provided to MANNATECH for the filing of any relevant patent applications. SGUL
shall remove any Confidential Information from any such submission at MANNATECH’s request. 
 10.2 In the event MANNATECH elects to enter into a
commercial venture with regard to the PROJECT findings, SGUL agrees to delay publication for a maximum of six months where required by MANNATECH. 
  

	11.	Publicity and Use of Name 

 MANNATECH and SGUL agree not to
use each other’s names, or the names of any staff members or employees thereof, in advertising, sales promotion work, or in any other form of publicity except with the written permission of, and to the extent approved by the party whose name is
to be used, except that MANNATECH may disclose the existence and scope of the PROJECT. 
  

	12.	Reports 

 12.1 The Lead Investigator shall furnish to
MANNATECH written reports during the term of this Agreement summarizing the research being conducted, including but not limited to significant findings (whether positive or negative) with respect to the PROJECT if/and/when they occur. 
  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 6 OF 10

 12.2 The Lead Investigator shall also provide periodic reports, at least quarterly, to MANNATECH’S Scientific
Subcommittee of its Board of Directors. 
 12.3 Whenever requested by MANNATECH in writing, SGUL shall meet with MANNATECH’s representatives, including
but not limited to MANNATECH’S Board of Directors and/or any subcommittee thereof, in the UK or by telephone to discuss research results and/or the Reports prepared by the Lead Investigator or designee arising from the PROJECT. 
  

	13.	Assignment 

 13.1 Neither party may assign or otherwise
transfer this Agreement and the rights acquired hereunder without the written consent of the other party; this consent shall not be unreasonably withheld. However, MANNATECH may assign or transfer its interest in this Agreement as long as such
assignment or transfer is accompanied by a sale or other transfer of MANNATECH’S entire business or other business to which this Agreement relates. A party desiring to assign or transfer this Agreement shall give the other party thirty
(30) days prior notice of such assignment or transfer. If no reasonable objections are raised, then the assignment or transfer shall be deemed to have been approved. However, an assignment or transfer shall not be deemed to be approved unless
the party to which this Agreement is assigned agrees in writing to be bound by the terms and conditions of this Agreement. 
 13.2 This Agreement shall inure
to the benefit of and be binding upon the successors, assigns, heirs, and personal representatives of the parties hereto. 
  

	14.	Notice 

 Any notices required to be given under the terms
and conditions of this Agreement shall be in writing and sent by first-class mail, with a confirmation by facsimile, addressed to each party as follows: 
 If to MANNATECH: 
 MANNATECH, INC. 
 Attn: General Counsel, Keith Clark 
 600 S. Royal Lane, Suite 200, 
 Coppell, Texas 75019 
 Fax: (972) 471-7389 
 If
to the SGUL: 
 St. George’s University of London 
 Attn: Head of Research, Development and Enterprise, 
 Dr. Sharon Spencer 
 Cranmer Terrace, 
 London SW17 ORE 
 Fax:+44(208) 725-0312 
 Notices under this
Agreement that are sent by one party as set forth above shall be considered given as of the date received by the other party. 
  

	15.	Independent Contractor 

  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 7 OF 10

 In the performance of all services hereunder, SGUL shall be deemed to be an independent contractor and as such, shall not
be entitled to any benefits applicable to employees of MANNATECH. Neither party is authorized or empowered to act as agent for the other for any purpose and shall not, on behalf of the other enter into any contract, warranty or representation as to
any matter. 
  

	16.	Independent Judgment 

 The Parties acknowledge that:
(a) they have read this Agreement; (b) they understand the terms and conditions of this Agreement; (c) they have had the opportunity to seek legal counsel and advice; (d) are of equal bargaining power; and (e) they have
relied on their own judgment in entering into this Agreement. 
  

	17.	Insurance 

 SGUL warrants and represents that it has and
will hold for the duration of the Study adequate liability insurance, such protection being applicable to officers, employees, and agents while acting within the scope of their employment with SGUL. MANNATECH warrants and represents that it has and
maintains insurance covering its legal liability resulting from the administration of Ambrotose in accordance with the Protocol. 
  

	18.	Indemnification 

 The Parties hereby waive and agree to
indemnify, defend and hold harmless the other party, it’s officers, trustees, agents, employees and students from any loss, claim, damages, or liability of any kind, including reasonable legal fees, court costs and other expenses in litigation
or settlement of any claims arising out of or in connection with this Agreement, except to the extent that such loss, claim of damage or liability arises in whole or in part from the negligence of the other party. The provisions of this paragraph
shall survive the termination of this Agreement. 
  

	19.	Export Controls 

 The Parties acknowledges that they are
subject to United States and United Kingdom laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities, and that its obligations under the terms and conditions of this Agreement are
contingent upon compliance with applicable United States and United Kingdom export laws and regulations and the approval of any export license by the governments of the United States and United Kingdom that may be required. The Parties agree to
cooperate in applying for and obtaining any necessary export license, but makes no representation or warranty that any such license will be granted. 
  

	20.	Governing Law 

 The Parties hereto agree that this Agreement
shall be governed by the laws of the State of Texas without regard to the conflicts of law principals. The Parties further agree that exclusive jurisdiction and venue to enforce the arbitration provisions of this agreement shall be in a state or
federal court of appropriate jurisdiction in Dallas County, Texas. Each party consents to personal jurisdiction in Dallas County, Texas, for any action to 

  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 8 OF 10

 
enforce arbitration including any further rules provided for emergency or extraordinary relief, as to this Agreement. 
  

	21.	Arbitration. 

 Both Parties hereby agree on behalf of
themselves and any persons claiming by or through them that any dispute, except insofar as such dispute is an Exempted Dispute (as defined below) arising out of or in connection with the execution, interpretation, performance, or nonperformance of
this Agreement shall be solely and finally settled by binding arbitration in accordance with the International Arbitration Rules of the American Arbitration Association in effect on the Effective Date of this Agreement (the “Rules”);
provided, however, that in the event of conflict between the Rules and the terms of this Agreement, the terms of this Agreement shall govern. The sole location and venue of arbitration shall be Dallas, Texas. The arbitration shall be conducted in
English and the arbitrator(s) shall apply the law chosen as the governing law of this Agreement. To commence arbitration of any such dispute, the Party desiring arbitration shall notify the other Party in writing in accordance with the Rules. The
Parties agree that the award of the arbitrator(s) shall be (i) the sole and exclusive remedy between them regarding any claims, counterclaims, or issues presented to the arbitrator(s), and (ii) final and subject to no judicial review. The
Parties further agree that any costs, fees, or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the Party resisting such enforcement. The Parties hereto agree that any judgment upon the
arbitration award rendered by the arbitrator(s) may be entered and enforced in any court having jurisdiction over the Parties or their assets. Each Party shall, except as otherwise provided herein, be responsible for its own expenses, including
legal fees, incurred in the course of any arbitration proceedings. In addition to the award, the arbitrator shall have the power to allocate the fees and expenses of the arbitration, including the Parties’ legal expenses, in such manner as the
arbitrator deems equitable based on the decision on the merits of the case. For the purposes of this Section 8.10, an “Exempted Dispute” means (i) any dispute involving any right or claim regarding any infringement, threatened or
alleged infringement, right to, title to or ownership of, or provision in this Agreement relating to, any Intellectual Property Rights of a Party or any of its affiliates, or (ii) any injunctive relief for violation or threatened or alleged
violation of the obligations under this Agreement, or (iii) any legal proceeding threatened, initiated or brought by a third party against both Parties or either Party, or any cross-claim or third-party claim in such third party’s legal
proceeding by either Party against the other Party. Except where clearly prevented by the area in dispute, the Parties agree to continue to perform their obligations under this Agreement while the dispute is being resolved unless and until this
Agreement expires or its terminated in accordance with its terms. 
  

	22.	Modifications 

 This Agreement may be changed, amended,
modified or extended only by a writing duly executed by the respective parties hereto. 
  

	23.	Force Majeure 

 Neither party shall be liable for any
failure to perform as required by this Agreement, to the extent such failure to perform is caused by any reason beyond its control, or by reason 

  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 9 OF 10

 
of any of the following occurrences: labor disturbances or labor disputes of any kind, accidents, failure of any governmental approval required for full
performance, civil disorders or commotions, acts of terrorism, floods, earthquakes, acts of God, energy or other conservation measures, explosion, failure of utilities, mechanical breakdowns, material shortages, disease or other such occurrences.

  

	24.	Severability 

 The provisions of this Agreement are
separable, and in the event any provisions of this Agreement are determined to be invalid or unenforceable under any controlling body of law, such invalidity or unenforceability shall not in any way affect the validity or enforceability of the
remaining provisions hereof. 
  

	25.	Headings 

 The paragraph headings herein are for convenience
only and shall not affect the construction or interpretation of this Agreement. 
  

	26.	Entire Agreement 

 This Agreement represents and embodies
all the agreements and negotiations between the parties hereto and no prior or contemporaneous, oral, or written agreements or correspondence prior to the date of execution of this agreement shall be held to vary the provisions hereof. 

In witness whereof, the hands of the parties or their duly authorized representatives on 3rd day of January, 2007. 
  
  

			
	ST. GEORGE’S HOSPITAL MEDICAL SCHOOL
		
	By:	 	/s/ John Duffy
		 	Mr John Duffy
		
	Its:	 	Director of Administration

  
  

			
	PRINCIPAL INVESTIGATOR
		
	By:	 	/s/ John Axford
		 	Prof John Axford

  
  

			
	MANNATECH, INC.
		
	By:	 	/s/ Samuel Caster
		 	Mr Samuel Caster
		
	Its:	 	Chairman & CEO

  

			
	 CLINICAL TRIAL RESEARCH AGREEMENT
	 	PAGE 10 OF 10Amended and Restated Transitional Compensation Agreement

 Exhibit 10.12 
 AMENDED AND RESTATED 
 TRANSITIONAL COMPENSATION AGREEMENT 
 AGREEMENT by and between AMCORE Financial, Inc., a Nevada corporation (the “Company”),
and [Participant] (the “Executive”), dated as of the 2nd day of January 2008. This Agreement
amends, restates and supersedes any and all prior agreements between the Company and the Executive relating to the subject matter of this Agreement, including (but not by way of limitation) the Transitional Compensation Agreement dated
April 30, 2007. 
 The Board of Directors of the Company (the “Board”) has determined that it is in the best interests
of the Company and its shareholders to assure that the Company will have the continued dedication of the Executive, notwithstanding the possibility, threat or occurrence of a Change of Control (as defined below) of the Company. The Board believes it
is imperative to diminish the inevitable distraction of the Executive by virtue of the personal uncertainties and risks created by a pending or threatened Change of Control, to encourage the Executive’s full attention and dedication to the
Company currently and in the event of any threatened or pending Change of Control, and to provide the Executive with compensation and benefit arrangements upon a Change of Control which ensure that the compensation and benefits expectations of the
Executive will be satisfied and which are competitive with those of other similar corporations. 
 Therefore, in order to accomplish these
objectives, the Board has caused the Company to enter into this Agreement. 
 As a condition to the effectiveness of this Agreement, the
Executive has executed the Confidentiality and Non-Competition Agreement attached hereto as Exhibit A. 
 NOW, THEREFORE, IT IS HEREBY AGREED
AS FOLLOWS: 
 1. Certain Definitions. 
 (a) The “Effective Date” shall mean the first date during the Change of Control Period (as defined in paragraph (b), below) on which a Change of Control (as defined in Section 2) occurs. Anything in
this Agreement to the contrary notwithstanding, if a Change of Control occurs and if the Executive’s employment 

 
with the Company is terminated or the Executive ceases to be an officer of the Company prior to the date on which the Change of Control occurs, and if it is
reasonably demonstrated by the Executive that such termination of employment or cessation of status as an officer (i) was at the request of a third party who has taken steps reasonably calculated to effect the Change of Control, or
(ii) otherwise arose in connection with or anticipation of the Change of Control and was not (A) for conduct by the Executive of the type described in Section 4(b), below, (B) for significant deficiencies in the Executive’s
performance of his duties to the Company (including, but not by way of limitation, significant failure to cooperate in implementing a decision of the Board), or (C) for some other specific substantial business reason unrelated to the Change of
Control, then for all purposes of this Agreement the “Effective Date” shall mean the date immediately prior to the date of such termination of employment or cessation of status as an officer. 
 (b) The “Change of Control Period” shall mean the period which commenced on April 30, 2007, and ending on the third
anniversary of such date; provided, however, that on April 30, 2008, and on each annual anniversary of such date (such date and each annual anniversary thereof being hereinafter referred to as a “Renewal Date”), this Agreement
and the Change of Control Period shall be automatically extended so as to terminate three (3) years from such Renewal Date, unless at least sixty (60) days prior to the Renewal Date the Company shall give notice to the Executive that the
Change of Control Period shall not be so extended, in which case this Agreement shall terminate upon the expiration of the Change of Control Period or, if an Effective Period (as defined in Section 3) is then in effect, upon the expiration of
the Effective Period. 
 2. Change of Control. For the purpose of this Agreement, a “Change of Control” shall mean the
occurrence, after the date hereof, of any of the following events: 
 (a) The acquisition, other than from the Company, by any
individual, entity or group (within the meaning of Section 13(d)(3) or l4(d)(2) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) of Company securities immediately after which such person is the beneficial owner
(within the meaning of Rule 13d-3 promulgated under the Exchange Act) of fifteen percent (15%) or more of either the then outstanding shares of common stock of the Company or the combined voting power of the then outstanding voting securities
of the Company entitled to vote generally in the election of directors, but excluding for this purpose any such acquisition by the Company or any of its subsidiaries, or any employee benefit plan (or related trust) of the Company or its
subsidiaries, or any corporation with respect to which, following such acquisition, more than sixty percent (60%) of, respectively, the then outstanding shares of common stock of such corporation and the combined voting power of the then
outstanding voting securities of such corporation entitled to vote generally in the election of directors is then 

  

 2 

 
beneficially owned, directly or indirectly, by all or substantially all of the individuals and entities who were the beneficial owners, respectively, of the
common stock and voting securities of the Company immediately prior to such acquisition in substantially the same proportion as their ownership, immediately prior to such acquisition, of the then outstanding shares of common stock of the Company or
the combined voting power of the then outstanding voting securities of the Company entitled to vote generally in the election of directors, as the case may be; or 
 (b) Individuals who, as of the date hereof, constitute the Board (the “Incumbent Board”) cease for any reason to constitute at
least a majority of the Board; provided that any individual becoming a director subsequent to the date hereof, whose election, or nomination for election by the Company’s shareholders, was approved by a vote of at least a majority of the
directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office is in connection with an actual
or threatened election contest, including, but not limited to, a consent solicitation, relating to the election of the directors of the Company (as such terms are used in Rule 14a-11 of Regulation l4A promulgated under the Exchange Act); or

 (c) There occurs (i) a reorganization, merger or consolidation of the Company or any direct or indirect subsidiary of
the Company, in each case, with respect to which all or substantially all of the individuals and entities who were the respective beneficial owners of the common stock and voting securities of the Company immediately prior to such reorganization,
merger or consolidation do not, following such reorganization, merger or consolidation, beneficially own, directly or indirectly, more than sixty percent (60%) of, respectively, the then outstanding shares of common stock and the combined
voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the ultimate parent corporation of any corporation resulting from such reorganization, merger or consolidation, or
(ii) shareholder approval of a complete liquidation or dissolution of the Company, or (iii) the sale or other disposition of all or substantially all of the assets of the Company. 
 3. Effective Period. The Effective Period shall be in effect for the period commencing on the Effective Date and ending on the second anniversary
of such date (the “Effective Period”). 
 4. Termination of Employment. 
 (a) Death or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the
Effective Period. If the Company determines in good faith that the Disability of the Executive has 

  

 3 

 
occurred during the Effective Period (pursuant to the definition of Disability as set forth below), it may give to the Executive written notice in accordance
with Section 11(b) of this Agreement of its intention to terminate the Executive’s employment. In such event, the Executive’s employment with the Company shall terminate effective on the thirtieth (30th) day after receipt of such
notice by the Executive (the “Disability Effective Date”), provided that, within the thirty (30) days after such receipt, the Executive shall not have returned to full-time performance of the Executive’s duties. For purposes of
this Agreement, “Disability” shall mean the absence of the Executive from the Executive’s duties with the Company on a full-time basis for one hundred and eighty (180) consecutive business days as a result of incapacity due to
mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive’s legal representative (such agreement as to acceptability not to
be withheld unreasonably). 
 (b) Cause. 
 (i) The Company may terminate the Executive’s employment during the Effective Period for Cause and may suspend the Executive from his
duties with full pay and benefits if the Executive is indicted for a felony involving moral turpitude; provided, however, that the Executive will repay all amounts paid by the Company from the date of such suspension if the Executive is convicted of
such felony. For purposes of this Agreement, “Cause” shall mean (A) the willful and continued failure by the Executive to substantially perform the Executive’s duties with the Company (other than any such failure resulting from
the Executive’s incapacity due to physical or mental illness or any such actual or anticipated failure after the issuance of a Notice of Termination for Good Reason by the Executive pursuant to Section 4(d) hereof) after a written demand
for substantial performance is delivered to the Executive by the Board, which demand specifically identifies the manner in which the Board believes that the Executive has not substantially performed the Executive’s duties, or (B) the
willful engaging by the Executive in conduct which is demonstrably and materially injurious to the Company or its subsidiaries, monetarily or otherwise. For purposes of clauses (A) and (B) of this definition, (x) no act, or failure to
act, on the Executive’s part shall be deemed “willful” unless done, or omitted to be done, by the Executive not in good faith and without reasonable belief that the Executive’s act, or failure to act, was in the best interest of
the Company and (y) in the event of a dispute concerning the application of this provision, no claim by the Company that Cause exists shall be given effect unless the Company establishes to the Board by clear and convincing evidence that Cause
exists, and the Board adopts a finding to that effect. 
 (ii) A Notice of Termination for Cause must include a copy of a
resolution duly adopted by the affirmative vote of not less than three-quarters (3/4) of the entire membership of the Board at a meeting of the Board 

  

 4 

 
which was called and held for the purpose of considering such termination (after reasonable notice to the Executive and an opportunity for the Executive,
together with the Executive’s counsel, to be heard before the Board) finding that, in the good faith opinion of the Board, the Executive was guilty of conduct set forth in clause (A) or (B) of the definition of Cause herein, and
specifying the particulars thereof in detail. 
 (c) Good Reason. The Executive’s employment may be terminated
during the Effective Period by the Executive for Good Reason. For purposes of this Agreement, “Good Reason” shall mean: 
 (i) The assignment to the Executive of any duties inconsistent in any material respect with the Executive’s position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as in effect
immediately prior to the Effective Date, or any other action by the Company which results in a diminution in such position, authority, duties or responsibilities, including, without limitation, if the Executive was, immediately prior to the
Effective Date, an executive officer of a public company, the Executive ceasing to be an executive officer of a public company, but excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is
remedied by the Company within thirty (30) days after receipt of notice thereof given by the Executive; 
 (ii) Any
reduction by the Company in Executive’s compensation or benefits as in effect immediately prior to the Effective Date, other than an isolated, insubstantial and inadvertent reduction not occurring in bad faith and which is remedied by the
Company promptly after receipt of notice thereof given by the Executive; 
 (iii) The Company’s requiring the Executive
to be based at any office or location more than twenty (20) miles from that in effect immediately prior to the Effective Date; 
 (iv) Any purported termination by the Company of the Executive’s employment otherwise than as expressly permitted by this Agreement; or 
 (v) Any failure by the Company to comply with and satisfy Section 10(c) of this Agreement, provided that such successor has received at least ten (10) days’ prior written notice from the Company or the
Executive of the requirements of Section 10(c) of this Agreement. 
 For purposes of this Section 4(c), any good faith determination of “Good
Reason” made by the Executive shall be conclusive. 
  

 5 

 (d) Notice of Termination. Any termination by the Company for Cause, or by the
Executive for Good Reason, shall be communicated by a Notice of Termination to the other party given in accordance with Section 11(b) of this Agreement. For purposes of this Agreement, a “Notice of Termination” means a written notice
which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the
Executive’s employment under the provision so indicated and (iii), if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date shall be not more than fifteen
(15) days after the giving of such notice). The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any right of the
Executive or the Company hereunder or preclude the Executive or the Company from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder. 
 (e) Date of Termination. “Date of Termination” means (i), if the Executive’s employment is terminated by the Company
for Cause, or by the Executive for Good Reason, the date of receipt of the Notice of Termination or any later date specified therein, as the case may be, (ii), if the Executive’s employment is terminated by the Company other than for Cause or
Disability or by the Executive other than for good reason, the Date of Termination shall be the date on which the terminating party notifies the other party of such termination, and (iii), if the Executive’s employment is terminated by reason
of death or Disability, the Date of Termination shall be the date of death of the Executive or the Disability Effective Date, as the case may be. 
 (f) Separation From Service. “Separation From Service” means a termination of employment that meets the “separation from service” requirements under section 409A of the Internal Revenue Code
of 1986, as amended (the “Code”) and section 1.409A-1(h) of the regulations thereunder (as may be amended from time to time and including any successor thereto). 
 5. Obligations of the Company upon Termination. 
 (a) By Company Other Than for Cause or Disability or By Executive for Good Reason. If, during the Effective Period, the Company shall terminate the Executive’s employment other than for Cause or
Disability, or the Executive shall terminate employment for Good Reason: 
 (i) The Company shall pay to the Executive in a
lump sum the following amounts, payment to be made at the times described below: 
 (A) The sum of 
 (1) the Executive’s then-current annual base salary through the Date of Termination to the extent not theretofore paid, which amount
shall be paid in cash within 30 days after the Date of Termination; 
  

 6 

 (2) the product of (x) Executive’s Recent Average Bonus (as defined below) and
(y) a fraction, the numerator of which is the number of days in the then current fiscal year through the Date of Termination, and the denominator of which is three hundred and sixty-five (365). This amount shall be paid during the 30-day period
commencing six months subsequent to Executive’s Separation From Service, and, in order to compensate for the delay, the amounts to be paid shall be increased by six-months interest, computed at the prime rate as reported in the Wall Street
Journal on the nearest date preceding the Separation From Service (the “Prime Rate”);; 
 (3) any compensation
previously deferred by the Executive (together with any accrued interest or earnings thereon and as adjusted to reflect any other appreciation or depreciation in value) ) . This amount shall be paid in cash within 30 days after the Separation From
Service; provided that, the payment described in this section 5(a)(i)(A)(3) shall only be paid as an immediate lump sum if (x) a lump sum payment had been previously elected by the Executive in accordance with section 409A or (y) the
Separation From Service is within two years following the Change in Control and the Change in Control would also qualify as a Change in Control under section 409A and the regulations thereunder; and 
 (4) any accrued vacation pay; the extent not theretofore paid, which amount shall be paid in cash within 30 days after the Date of
Termination (the sum of the amounts described in parts (1), (2), (3) and (4), above, being hereinafter referred to as the “Accrued Obligations”). 
 For purposes of this Agreement, Executive’s Recent Average Bonus shall be the average annualized (for any fiscal year consisting of less than 12 full months or with respect to which the Executive has been employed by the Company for
less than 12 full months) bonus paid or payable, before taking into account any deferral, to the Executive by the Company and its affiliated companies in respect of the three fiscal years immediately preceding the fiscal year in which the
termination of the Executive’s employment occurs; provided, however, that (i) if the Executive was not employed by the Company for any full fiscal year that would otherwise be included in the calculation of Recent Average Bonus, that year
will be excluded from the calculation of Recent Average Bonus; and (ii) if the Executive was not employed by the Company for at least one full fiscal year during the period that would otherwise be included in the calculation of Recent Average
Bonus, the Executive’s Recent Average Bonus will instead be calculated as the Executive’s Target Bonus for the year in which the termination occurred; and 
  

 7 

 (B) The amount (such amount being hereinafter referred to as the “Severance
Amount”) equal to (i) the product of 1.00 multiplied by the Executive’s then-current annual base salary, plus (ii) the product of 1.00 multiplied by the Executive’s Recent Average Bonus; provided, however, that the aggregate
of such amounts shall be reduced by the present value (determined as provided in Section 280G(d)(4) the “Code”) of any other amount of severance relating to salary or bonus continuation to be received by the Executive, upon such
termination of employment, under any other severance plan, policy or arrangement of the Company. The Severance Amount (also referred to as the “Non-Compete Payment”) shall be deemed to be allocable to the performance of the covenants
applicable to Executive pursuant to the Confidentiality and Non-Competition Agreement attached hereto as Exhibit A. This amount shall be paid during the 30-day period commencing six months subsequent to Executive’s Separation From Service, and,
in order to compensate for the delay, the amounts to be paid shall be increased by six-months interest at the Prime Rate; and 
 (ii) At the Date of Termination, stock options, restricted stock, and other awards relating to stock under equity incentive plans or programs of the Company and its affiliates which would have become vested (non-forfeitable) if
Executive’s employment had continued for thirty-six (36) months thereafter, excluding awards that require performance goals to be achieved in addition to passage of time and continued employment, will be immediately vested and exercisable,
and any such stock options and other outstanding stock options already vested at or before the Date of Termination shall remain outstanding and exercisable for a period that is the greater of one year after the Date of Termination (but in no event
after the stated expiration date of such option) or such longer period as may be provided under the applicable plan or program, and any such awards subject to settlement at a date later than the vesting date shall be immediately settled; provided,
however, that rights set forth in this paragraph 5(a)(ii) shall be subject to the limitations described in Section 6; and 
 (iii) The Company shall pay to the Executive a lump sum equal to X, which amount shall be paid during the 30-day period commencing six months subsequent to Executive’s Separation From Service. For the purpose of the preceding sentence,
X equals the value of the benefits that would have been provided to Executive and/or the Executive’s family during the 12 month period immediately following the Date of Termination, if the Executive’s employment had not been terminated, in
accordance with (A) the welfare benefit plans, practices, programs or policies of the Company and its affiliated companies as in effect and applicable generally to other peer executives and their families or, if more favorable, applicable to
the Executive and his family during the ninety (90)-day period immediately 

  

 8 

 
preceding the Effective Date or (B) if more favorable to the Executive, those in effect generally from time to time thereafter with respect to other
peer executives of the Company and its affiliated companies and their families For the purpose of computing X with respect to benefits where the Company pays insurance premiums, the cost of benefits shall equal the insurance premiums that would have
been paid over such twelve (12) month period that provides benefits to the Executive, based on the insurance premiums in effect on the Date of Termination. For purposes of determining eligibility of the Executive for retiree benefits pursuant
to such plans, practices, programs and policies, the Executive shall be considered to have remained employed during the twelve (12) month period immediately following the Date of Termination and to have retired on the last day of such period
(and, to the extent Executive is eligible to receive retiree benefits that duplicate the benefits that would otherwise be taken into account in computing X, X shall be reduced); and 
 (iv) The Company shall pay to the Executive a lump sum equal to Y, which amount shall be paid during the 30-day period commencing six
months subsequent to Executive’s Separation From Service. For the purpose of the preceding sentence, Y equals the value of the benefits that would have been provided to Executive during the twelve (12) month period immediately following
the Date of Termination ( if the Company had continued to provide the Executive and his family with the benefits and perquisites at least equal to those which would have been provided to them if the Executive’s employment had not been
terminated, in accordance with the terms generally applicable with respect to the provision of such benefits and perquisites during the ninety (90) day period immediately preceding the Effective Date, or, if more favorable to the Executive, in
effect generally from time to time thereafter during such twelve(12) month period with respect to other peer executives of the Company and its affiliated companies and their families. These Benefits shall include (but shall not be limited to) the
following: employer contributions to the AMCORE Financial Security Plan, employer contributions to the AMCORE Deferred Compensation Plan, AMCORE Cash Profit Plan or any other defined contribution retirement plan, club membership fees, financial
planning allowance and car allowance. In computing Y, the Company shall determine the amount of a benefit annually provided by the Company by (A) assuming that the Executive’s base pay would have remained in effect at the rate in effect on
the Date of Termination and the Executive would have received annual bonuses equal to the Recent Average Bonus, and (B) assuming, in the case of club membership fees, financial planning allowance, car allowance, and similar benefits, that the
Executive would receive such benefits during the twelve months following the Date of Termination at the same rate that he received such benefits during the 12 months ending on the last day of the calendar quarter preceding the Date of Termination.

 (v) all amounts payable to the Executive pursuant to this Section 5 are subject to the limitations described in
Section 6 of this Agreement. 
  

 9 

 (b) Death. If the Executive’s employment is terminated by reason of the
Executive’s death during the Effective Period, this Agreement shall terminate without further obligations to the Executive’s legal representatives under this Agreement, other than for (i) payment of the Accrued Obligations (which
payments shall, notwithstanding the language of 5(a)(i)(A) above, be paid to the Executive’s estate or beneficiary, as applicable, in a lump sum in cash within thirty (30) days of the Date of Termination, and shall not include the interest
factor described in 5(a)(i)(A) above) and (ii) the payment of the benefits described in section 5(a)(iii) and (iv) (which payments shall, notwithstanding the language of 5(a)(iii) and (iv) above, be paid to the Executive’s estate
or beneficiary, as applicable, in a lump sum in cash within 30 days of the Date of Termination). 
 (c) Disability. If
the Executive’s employment is terminated by reason of the Executive’s Disability during the Effective Period, this Agreement shall terminate without further obligations to the Executive, other than for (i) payment of the Accrued
Obligations and (ii) the timely payment of the benefits described in section 5(a)(iii) and (iv), but for this purpose only computing the amount of such benefits that would have been payable during the 12 month period immediately following the
Date of Termination. Notwithstanding the language of section 5(a)(i)(A), (iii), and (iv), to the extent permitted under Section 409A, the payment of the obligations described in this subsection (c) shall be paid within 30 days of the Date
of Termination (and the interest factor described in section 5(a)(i)(A) shall not apply) if the Disability constitutes a disability within the meaning of section 409A of the Code and the regulations thereunder. 
 (d) Cause; Other than for Good Reason. If, during the Effective Period, the Executive’s employment shall be terminated by the
Company for Cause or the Executive terminates employment not for Good Reason: 
 (i) The Company may elect to have the
Confidentiality and Non-Competition Agreement attached hereto as Exhibit A become effective and remain in effect in accordance with the terms of that Agreement, by giving notice of such election to the Executive, not later than five
(5) business days after the effectiveness of the Executive’s termination of employment. 
 (ii) If the
Executive’s employment was terminated by the Company for Cause, the Company shall pay the Executive’s then current annual base salary through the Date of Termination, plus the amount of any compensation previously deferred by the Executive
(together with any accrued interest or earnings thereon and as adjusted to reflect any other appreciation or depreciation in value) and any accrued vacation pay; in each case to the extent theretofore unpaid; provided that the payment of previously
deferred compensation, as adjusted, shall only be paid as an immediate lump sum if (x) a lump sum payment had been previously elected by the Executive or (y) the Separation From Service is within two years following the Change in Control
and the Change in Control would also qualify as a Change in Control under section 409A and the regulations thereunder. 
  

 10 

 (iii) If the Executive terminates his employment other than for Good Reason, the Company
shall pay to the Executive the Accrued Obligations. In such case, all Accrued Obligations shall be paid to the Executive in a lump sum at the times set forth in section 5(a)(i)(A) above. 
 (iv) Upon payment by the Company of the applicable amounts under this Section 5(d), the Agreement shall terminate without further
obligations to the Executive. 
 6. Limitation of Payments and Certain Stock Option Rights. The parties agree that: 
 (a) Anything in this Agreement to the contrary notwithstanding, it is the intent of the parties hereto that no amount payable pursuant to
the terms of this Agreement shall cause any payment or transfer by the Company or for the benefit of Executive, whether paid or payable (or transferred or transferable) pursuant to the terms of this Agreement or otherwise, to be subject to taxation
under Section 4999 of the Code and as an “excess parachute payment” as defined in Section 280G of the Code. In the event that the last independent auditors selected by the Board prior to the termination of the Executive’s
employment (the “Auditors”) determine that any such item would result in a deduction disallowance and/or the imposition of an excise tax under Code Sections 280G and 4999, then the item shall be reduced by the amount necessary to avoid
such deduction disallowance and/or imposition of excise tax. 
 (b) The Auditors shall provide detailed supporting
calculations both to the Company and the Executive within fifteen (15) business days of receipt of a written request from the Company or the Executive for a determination as to whether reductions of a payment is necessary in order to avoid the
excise tax and/or deduction disallowance imposed by Sections 280G and 4999 of the Code. All fees and expenses of the Auditors shall be borne solely by the Company. If the Auditors determine that a payment under this Agreement (without reduction
pursuant to paragraph (a), above) will not be subject to the deduction disallowance and/or excise tax imposed by Sections 280G and 4999 of the Code, the Auditors shall furnish the Executive with a written opinion that failure to report, on the
Executive’s applicable federal income tax return, any excise tax in connection with such payment would not result in the imposition of a negligence or similar penalty. Any good faith determinations by the Auditors shall be binding upon the
Company and the Executive. 
 (c) Anything in this Agreement to the contrary notwithstanding, it is the intent of the parties
hereto that nothing in this Agreement, including without 

  

 11 

 
limitation any rights described in paragraph 5(a)(ii), shall cause any of the Executive’s outstanding stock options, restricted stock, and/or other
awards relating to stock under equity incentive plans or programs of the Company and its affiliates to be treated as a newly issued discount stock option subject to Code Section 409A and its implementing regulations, to violate the requirements
of Code Section 409A, and/or to result in the imposition of any penalty pursuant to Section 409A. Consequently, the parties agree that any rights to immediate vesting and exercise described in paragraph 5(a)(ii) of this Agreement shall be
limited, if necessary (but only to the extent necessary), to avoid any such result. 
 (d) The Auditors shall provide a
detailed opinion to the Company and the Executive within fifteen (15) business days of receipt of a written request from the Company or the Executive for a determination as to whether any limitation in the rights described in paragraph 5(a)(ii)
(or any other provision of this Agreement) is necessary in order to avoid any violation of Code Section 409A and/or the imposition of a penalty pursuant to Code Section 409A. Any good faith determinations by the Auditors shall be binding
upon the Company and the Executive. 
 7. Non-exclusivity of Rights. Except as explicitly provided in this Agreement, nothing in this
Agreement shall prevent or limit the Executive’s continuing or future participation in any plan, program, policy or practice provided by the Company or any of its affiliated companies and for which the Executive may qualify, nor shall anything
herein limit or otherwise affect such rights as the Executive may have under applicable law or under any other contract or agreement with the Company or any of its affiliated companies. Amounts which are vested benefits or which the Executive is
otherwise entitled to receive under any other plan, policy, practice or program of; or any other contract or agreement with, the Company or any of its affiliated companies at, or subsequent to, the Date of Termination shall be payable in accordance
with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement. 
 8. Full
Settlement; Resolution of Disputes. 
 (a) The Company’s obligation to make the payments provided for in this
Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or action which the Company may have against the Executive or others (except as specifically
provided with respect to the Non-Compete Payment). In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of this
Agreement and, except as provided in Section 5(a)(iii) of this Agreement, such amounts shall not be reduced whether or not the Executive obtains other employment. The Company agrees to pay promptly upon receipt of proper invoices, 

  

 12 

 
to the fullest extent permitted by law, all legal fees and expenses which the Executive may reasonably incur as a result of any contest by the Company, the
Executive or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of any contest initiated by the Executive about the amount of any payment
due pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable federal rate provided for in Section 7872(f)(2)(A) of the Code; provided, however, that in the event that it is finally judicially determined
that the Executive was terminated for Cause, then the Executive shall be obligated to repay to the Company the full amount of all such legal fees and expenses paid for the Executive by the Company in connection with that contest, plus interest at
the rate described above. 
 (b) If there shall be any dispute between the Company and the Executive (i) in the event of
any termination of the Executive’s employment by the Company, whether such termination was for Cause, or (ii) in the event of any termination of employment by the Executive, whether Good Reason existed, then, unless and until there is a
final, nonappealable judgment by a court of competent jurisdiction declaring that such termination was for Cause or that the determination by the Executive of the existence of Good Reason was not made in good faith, the Company shall pay all
amounts, and provide all benefits, to the Executive and/or the Executive’s family or other beneficiaries, as the case may be, that the Company would be required to pay or provide pursuant to Section 5(a) hereof as though such termination
were by the Company without Cause or by the Executive with Good Reason; provided, however, that the Company shall not be required to pay any disputed amounts pursuant to this paragraph except upon receipt of an undertaking by or on behalf of the
Executive and/or the other recipient(s), as the case may be, to repay all such amounts to which the Executive or other recipient, as the case may be, is ultimately adjudged by such court not to be entitled. 
  

 13 

 9. Confidential Information. The Executive shall hold in a fiduciary capacity for the benefit of
the Company all secret or confidential information, knowledge or data relating to the Company or any of its affiliated companies, and their respective businesses, which shall have been obtained by the Executive during the Executive’s employment
by the Company or any of its affiliated companies and which shall not be or become public knowledge (other than by acts by the Executive or representatives of the Executive in violation of this Agreement). After termination of the Executive’s
employment with the Company, the Executive shall not, without the prior written consent of the Company or as may otherwise be required by law or legal process, communicate or divulge any such information, knowledge or data to anyone other than the
Company and those designated by it. However, in no event shall an asserted violation of the provisions of this Section 9 constitute a basis for deferring or withholding any amounts otherwise payable to the Executive under this Agreement.

 10. Successors. 
 (a) This Agreement is personal to the Executive and, without the prior written consent of the Company, no obligations or rights hereunder shall be assignable by the Executive otherwise than by will or the laws of
descent or distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive’s legal representatives. 
 (b) This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. 
 (c) The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company to assume expressly and
agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company” shall mean the Company as hereinbefore
defined and any successor to its business and/or assets as aforesaid which assumes and agrees to perform this Agreement, by operation of law or otherwise. 
 11. Miscellaneous. 
 (a) This Agreement shall be governed by and construed in
accordance with the laws of the State of Illinois, without reference to principles of choice of law. The captions of this Agreement are for convenience only and are not part of the provisions hereof and shall have no force or effect. This Agreement
may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. 
  

 14 

 (b) All notices and other communications hereunder shall be in writing and shall be given
to the other party by hand delivery or commercial messenger delivery or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: 
 If to the Executive: 
 [Participant name and address] 
 If to the Company: 
 AMCORE Financial, Inc. 
 501 Seventh Street 
 P.O. Box 1537 
 Rockford, Illinois 61110-0037 
 Attention: Mr. James S. Waddell 
 or to such other address as either party shall have furnished to the other in
writing in accordance herewith. Notice and communications shall be effective when actually received by the addressee. 
 (c)
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. 
 (d) The Company may withhold from any amounts payable under this Agreement such federal, state or local taxes as shall be required to be
withheld pursuant to any applicable law or regulation. 
 (e) The Executive’s or the Company’s failure to insist
upon strict compliance with any provision hereof or the failure to assert any right that the Executive or the Company may have hereunder, including, without limitation, the right of the Executive to terminate employment for Good Reason pursuant to
Section 4(c) of this Agreement, shall not be deemed to be a waiver of such provision or right or of any other provision of or right under this Agreement. 
 (f) The Executive and the Company acknowledge that this Agreement is not a contract of employment and that, except as may otherwise be
provided under any other written agreement between the Executive and the Company, the employment of the Executive by the Company is, and shall remain during the Effective Period, “at will” and may, subject to Section 5, above, be
terminated by either the Executive or the Company at any time. Moreover, subject to Section 1, above, if prior to the Effective Date (i) the Executive’s employment with the Company and all affiliates terminates or (ii) the
Executive ceases to be an officer of the Company and of all affiliates, then the Executive shall have no further rights under this Agreement. 
  

 15 

 (g) This Agreement embodies the entire agreement and understanding between the Company
and the Executive and supersedes all prior agreements and understandings between the Company and Executive relating to the subject matter hereof. 
 (h) The provisions of this Agreement are intended to comply with section 409A as it applies to an individual who is a “specified employee” as defined in section 409A. To the extent any provision is
inconsistent with section 409A, it shall be deemed modified so that the modified provision is consistent with section 409A. 
 IN WITNESS
WHEREOF, the Executive has hereunto set the Executive’s hand and, pursuant to the authorization of its Board of Directors, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above
written. 
  

			
	AMCORE FINANCIAL, INC.
		
	By:	 	/s/ James S. Waddell
		 	James S. Waddell
	Its	 	Executive Vice President & Chief
Administrative Officer
		
	By:	 	 
		 	[Participant] (“Executive”)

  

 16 

 AMENDED AND RESTATED 
 EXHIBIT A 
 CONFIDENTIALITY AND NON-COMPETITION AGREEMENT 
 CONFIDENTIALITY AND NON-COMPETITION AGREEMENT, dated as of January 2, 2008, by and between AMCORE Financial, Inc. (the “Company”)
and [Participant] (“Executive”). 
 Section 1. Non-Competition; Non-Solicitation. 
 (a) During the period beginning on the “Effective Date,” as that term is defined in the Transitional Compensation Agreement of
even date herewith, and continuing while Executive is serving as an executive officer of the Company and for one year following the termination of Executive’s employment with the Company, any successor thereto, and its or their subsidiaries
(the “Noncompetition Period”), if such termination of employment occurs within one year after the Effective Date and Executive becomes entitled to receive the “Non-Compete Payment” as defined in Section 5 of the Transitional
Compensation Agreement, Executive will not, within fifty (50) miles of the Company’s headquarters in Rockford, Illinois as of the Effective Date, engage in “Competition” with the Company. For purposes of this Confidentiality and
Non-Competition Agreement, Competition by Executive shall mean Executive’s: 
 (i) engaging in, including without
limitation consulting or start-up activities for Executive’s own account or any third party, the business of commercial banking (including trust and asset management and mortgage banking); or 
 (ii) becoming interested in, or otherwise directly or indirectly being employed by or acting as a consultant or lender to, or render any
services to, or being a director, officer, employee, principal, agent, stockholder, manager, member, owner or partner of, employer of, or permitting his name to be used in connection with the activities of any other business or organization (a
“Competing Business”) which engages in, or is preparing to engage in, the business of commercial banking (including trust and asset management and mortgage banking); provided, however, that, notwithstanding the foregoing, it shall not be a
violation of this Section 2(a) for Executive to become the registered or beneficial owner of up to two(2%) percent of any class of the capital stock of a Competing Business registered under the Securities Exchange Act of 1934, as amended,
provided that Executive does not otherwise participate in the business of such corporation. 

 (b) during the Noncompetition Period, Executive will not in any manner, directly or
indirectly: 
 (i) solicit (or cause, or authorize, to be solicited), divert or otherwise attempt to obtain the business of
any person who is, or has at any time within three years prior to the date of such action been, a customer, supplier, licensee or business relation of the Company for any purpose which is competitive with the Company’s business; 
 (ii) intentionally disturb or attempt to disturb in any adverse respect any business relationship between any person and the Company;

 (iii) solicit from any customer of the Company, or from any known potential customer of the Company, business which has
been the subject of a known written or oral bid, offer or proposal by the Company, or of substantial preparation with a view to making such a bid, proposal or offer, in any case, during the two-year period immediately preceding the termination for
any reason whatsoever of his service with the Company; 
 (iv) seek or attempt to persuade, induce or encourage any director,
officer, employee, consultant, advisor or other agent of the Company to discontinue his or her status or employment therewith or to become employed or otherwise engaged in a Competing Business; and 
 (v) solicit or employ, or otherwise hire or engage as an employee, independent contractor, consultant, advisor or otherwise, any person at
any time within 12 months following the date of cessation of employment of such person or the termination of such person’s other status, as the case may be, with the Company. 
 Section 2. Confidentiality; Intellectual Property; Disclosure. 
 (a) Except as otherwise provided in this Confidentiality and Non-Competition Agreement, at all times hereafter, Executive shall keep
secret and retain in strictest confidence, any and all Confidential Information (as hereinafter defined) relating to the Company, and shall use such Confidential Information only 

  

 A-2 

 
in furtherance of the performance by him of his duties as an executive officer of the Company and not for personal benefit or the benefit of any interest
adverse to the interests of the Company. For purposes of this Confidentiality and Non-Competition Agreement, “Confidential Information” shall mean any confidential or proprietary information including, without limitation, plans,
specifications, models, samples, data, customer lists and customer information, computer programs and documentation, and other technical and/or business information, in whatever form, tangible or intangible, printed, electronic or magnetic, that can
be communicated by whatever means available at such time, that relates to the Company’s current business or future business contemplated during the period Executive serves as an executive officer of the Company, products, services and/or
developments, or information received from others that the Company is obligated to treat as confidential or proprietary, and Executive shall not disclose such Confidential Information to any person other than the Company, except as may be required
by law or court or administrative order (in which event Executive shall so notify the Company as promptly as practicable). Upon the termination of Executive’s position as an executive officer of the Company for any reason, Executive shall
promptly return to the Company or destroy all copies, reproductions and summaries of Confidential Information in his possession or control and erase the same from all media in his possession or control, and, if the Company so requests, shall certify
in writing that he has done so. All Confidential Information is and shall remain the property of the Company, or in the case of information that the Company receives from a third party which it is obligated to treat as confidential, then the
property of such third party. 
 (b) All Intellectual Property (as hereinafter defined) created, developed, co-developed,
obtained or conceived of by Executive during the period Executive is serves as an executive officer of the Company, and all business opportunities presented to Executive during the period Executive serves as an executive officer of the Company,
shall be owned by and belong exclusively to the Company, provided that they reasonably relate to any of the business of the Company on the date of such creation, development, obtaining or conception, and Executive shall (i) promptly disclose
any such Intellectual Property or business opportunity to the Company, and (ii) promptly execute and deliver to the Company, without additional compensation, such instruments as the Company may require from time to time to evidence its
ownership of any such Intellectual Property or business opportunity (the “Intellectual Property Documents”). If the Company is unable because of Executive’s mental or physical incapacity or for any other reason to secure
Executive’s signature for any Intellectual Property Document, then Executive hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his agent and attorney in fact, to act for and in his behalf and
stead to execute and file any Intellectual Property Document and to do all other lawfully permitted acts to evidence or perfect the Company’s ownership and 

  

 A-3 

 
rights of and to any Intellectual Property or business opportunity with the same legal force and effect as if executed by Executive. For purposes of this
Confidentiality and Non-Competition Agreement, the term “Intellectual Property” means any and all of the following and all statutory and/or common law rights throughout the world in, arising out of, or associated therewith: (i) all
patents and applications therefor, including docketed patent disclosures awaiting filing, reissues, divisions, renewals, extensions, provisionals, continuations and continuations-in-part thereof; (ii) all inventions (whether patentable or not),
inventions disclosures and improvements, all trade secrets, confidential business information (including ideas, research and development, know-how, compositions, designs, specifications, pricing and cost information and business and market plans and
proposals), proprietary information, manufacturing, engineering and technical drawings and specifications, processes, designs and technology; (iii) all works of authorship, “moral rights,” copyrights (including derivative works
thereof), mask works, copyright and mask work registrations and applications therefor; (iv) all trade names, trade dress, logos, product names, collective marks, collective membership marks, trademarks certification marks and service marks,
trademark and service mark registrations and applications together with the goodwill of the business symbolized by the names and the marks; (v) all data and related documents, object code, databases, passwords, encryption technology, firmware,
development tools, files, records and data, and all media on which any of the foregoing is recorded; (vi) any similar, corresponding or equivalent rights to any of the foregoing; (vii) all documentation related to any of the foregoing; and
(viii) all goodwill associated with any of the foregoing. 
 Section 3. Non-Disparagement. 
 Executive shall not, at any time from and after the Effective Date, make statements or representations, or otherwise communicate, directly
or indirectly, in writing, orally, or otherwise, or take any action which may, directly or indirectly, disparage or be damaging to the Company, its successors, subsidiaries or affiliates or their respective officers, directors, employees, advisors,
businesses or reputations, and the Company, its successors, subsidiaries and affiliates and their respective officers, employees, and agents shall not make any such statements or representations regarding Executive. Notwithstanding the foregoing,
nothing in this Agreement shall preclude Executive or any other person from making truthful statements that are required by applicable law, regulation or legal process. 
 Section 4. Cooperation With Regard to Litigation. 
 Executive agrees to cooperate
with the Company, at any time from and after the Effective Date (including following Executive’s termination of employment), by making himself available to testify on behalf of the Company or 

  

 A-4 

 
any successor, subsidiary or affiliate of the Company, in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to
assist the Company, or any successor, subsidiary or affiliate of the Company, in any such action, suit, or proceeding, by providing information and meeting and consulting with the Board or its representatives or counsel, or representatives or
counsel to the Company, or any subsidiary or affiliate of the Company, as may be reasonably requested and after taking into account Executive’s responsibilities and obligations to third parties. The Company agrees to reimburse Executive, on an
after-tax basis, for all expenses actually incurred in connection with his provision of testimony or assistance hereunder. 
 Section 5.
Covenants Reasonable. 
 Executive hereby acknowledges that the business of the Company is highly competitive.
Executive further acknowledges that this Confidentiality and Non-Competition Agreement is being entered into in connection with the Transitional Compensation Agreement, that his service to the Company will be of a special and unique character, and
that he will continue to be identified personally with the Company. Executive also acknowledges that service as an executive officer of the Company will require that he have access to some of the Company’s most highly confidential business
information, trade secrets and proprietary information. The parties therefore acknowledge that the restrictions contained in Sections 1 and 2 hereof are a reasonable and necessary protection of the immediate interests of the Company, and any
violation of these restrictions would cause substantial injury to the Company and that the Company would not have entered into the Transitional Compensation Agreement and this Confidentiality and Non-Competition Agreement without receiving the
additional consideration offered by Executive in binding himself to any of these restrictions. 
 Section 6. Governing Law; Consent
to Jurisdiction; Injunctive Relief. 
 This Confidentiality and Non-Competition Agreement shall be governed by, and
construed and enforced in accordance with, the laws of the State of Illinois, without regard to its conflict of laws provisions. In the event of a breach or threatened breach by Executive of any of these restrictions, the Company shall be entitled
to apply to any court of competent jurisdiction for an injunction restraining Executive from such breach or threatened breach; provided, however, that the right to apply for an injunction shall not be construed as prohibiting the Company from
pursuing any other available remedies for such breach or threatened breach. 
  

 A-5 

 Section 7. Notices. 
 Unless otherwise provided herein, any notice, exercise of rights or other communication required or permitted to be given hereunder shall
be in writing and shall be given by overnight delivery service such as Federal Express, telecopy (or like transmission) or personal delivery against receipt, or mailed by registered or certified mail (return receipt requested), to the party to whom
it is given at such party’s address set forth below such party’s name on the signature page or such other address as such party may hereafter specify by notice to the other party hereto. Any notice or other communication shall be deemed to
have been given as of the date so personally delivered or transmitted by telecopy or like transmission or on the next business day when sent by overnight delivery service. 
 Section 8. Amendment. 
 This Confidentiality and Non-Competition Agreement may be amended, modified, superseded or canceled, and the terms and covenants hereof may be waived, only by a written instrument executed by both of the parties hereto, or in the case of a
waiver, by the party waiving compliance. The failure of either party at any time or times to require performance of any provision hereof shall in no manner affect the right at a later time to enforce the same. 
 Section 9. Binding Effect. 
 This Confidentiality and Non-Competition Agreement is not assignable by Executive. This Confidentiality and Non-Competition Agreement shall be binding upon and inure to the benefit of the Company and any successor
organizations which shall succeed to the Company by merger or consolidation or operation of law or otherwise, or by acquisition of all or substantially all of the assets of the Company. 
 Section 10. Severability. 
 Executive acknowledges and agrees that the restrictive covenants and agreements contained herein (the “Restrictive Covenants”) are reasonable and valid in geographic and temporal scope and in all other
respects, and do not impose limitations greater than that are necessary to protect the goodwill, the confidential information and any other business interests of the Company, or any of its successors or assigns. If, however, any court subsequently
determines that any of such covenants or agreements, or any part thereof, is invalid or unenforceable, the remainder of such covenants and agreements shall not thereby be affected and shall be given full effect without regard to the invalid portions
thereof. In addition, if any 

  

 A-6 

 
court construes any of the Restrictive Covenants, or any part thereof, to be unenforceable because of the duration of such provision or the area covered
thereby, such court shall have the power to reduce the duration or area of such provision and, in its reduced form, such provision shall then be enforceable and shall be enforced. 
 Section 11. Execution in Counterparts. 
 This Confidentiality and Non-Competition Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original and all of which shall constitute one and the same instrument.

 Section 12. Entire Agreement. 
 This Confidentiality and Non-Competition Agreement (together with applicable provisions of the Transitional Compensation Agreement) sets forth the entire agreement, and supersedes all prior agreements and any other
agreement between the parties and understandings, both written and oral, between the parties with respect to the subject matter hereof as applicable to any period after the Effective Date (except for other agreements relating to confidentiality,
proprietary information and intellectual property as may be entered into by Executive and the Company or any subsidiary or affiliate). 
 Section 13. Titles and Headings. 
 Titles and headings to Sections herein are for purposes of reference
only, and shall in no way limit, define or otherwise affect the meaning or interpretation of any of the provisions of this Confidentiality and Non-Competition Agreement. 
 Section 14. Conflicts of Interest; Representations and Warranties. 
 Executive
specifically covenants, warrants and represents to the Company that he has the full, complete and entire right and authority to enter into this Confidentiality and Non-Competition Agreement, that he has no agreement, duty, commitment or
responsibility or obligation of any kind or nature whatsoever with any corporation, partnership, firm, company, joint venture or other person which would conflict in any manner whatsoever with any of his duties, obligations or responsibilities to
the Company pursuant to this Confidentiality and Non-Competition Agreement or which could interfere with Executive’s performance under this Confidentiality and Non-Competition Agreement, that he is not in possession of any document or other
tangible property of any other person of a confidential or proprietary nature which would conflict in any manner whatsoever with any of his duties, obligations or responsibilities to the Company pursuant to this 

  

 A-7 

 
Confidentiality and Non-Competition Agreement and Executive’s performance of his obligations to the Company will not breach any agreement by which
Executive is bound not to disclose any proprietary information, and that he is fully ready, willing and able to perform each and all of his duties, obligations and responsibilities pursuant to this Confidentiality and Non-Competition Agreement.

 IN WITNESS WHEREOF, the undersigned have executed this Confidentiality and Non-Competition Agreement. 
  

			
		 	 
	Name:	 	[Participant]
	Address:	 	[Participant address]

  

			
	AMCORE FINANCIAL, INC.
		
	By:	 	/s/ James S. Waddell
	Name:	 	James S. Waddell
	Title:	 	EVP & CAO
	Address:	 	AMCORE Financial, Inc.
		 	 501 Seventh Street
 Rockford, Illinois
61104

  

 A-8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00139-of-00352.parquet"}]]